Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Alumis in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings per share of ($4.13) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.15) per share.
A number of other equities research analysts have also issued reports on ALMS. Robert W. Baird initiated coverage on shares of Alumis in a research note on Thursday, October 31st. They issued an "outperform" rating and a $25.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $26.00 price objective on shares of Alumis in a report on Monday, January 6th. Finally, Baird R W raised Alumis to a "strong-buy" rating in a report on Thursday, October 31st. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $26.83.
View Our Latest Report on Alumis
Alumis Price Performance
NASDAQ ALMS traded down $0.33 during trading hours on Thursday, reaching $6.57. 640,715 shares of the company traded hands, compared to its average volume of 143,086. Alumis has a 12 month low of $6.40 and a 12 month high of $13.53. The stock has a 50 day simple moving average of $8.43.
Institutional Trading of Alumis
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Alumis during the 3rd quarter valued at about $27,000. MetLife Investment Management LLC bought a new stake in shares of Alumis during the third quarter valued at approximately $89,000. JPMorgan Chase & Co. acquired a new position in shares of Alumis during the third quarter worth approximately $191,000. Barclays PLC bought a new position in Alumis in the 3rd quarter worth approximately $197,000. Finally, Maven Securities LTD acquired a new stake in Alumis in the 2nd quarter valued at approximately $332,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
